2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1274

Atmospheric Temperature and the Incidence of Gout Flare: Data from the Korea Meteorological Association and National Health Insurance Service
Abstract Number: 1713

Attainment of Low Disease Activity and Remission in SLE Patients Who Started with High Disease Activity in the Atacicept Phase IIb Address II Study and Its Long-Term Extension
Abstract Number: 2353

Attitudes and Beliefs Regarding Methotrexate in Patients with Rheumatoid Arthritis: Results from Australian Rheumatology Association Database
Abstract Number: 2351

Attitudes Toward Telehealth Video Conferencing Among Patients with Rheumatic Disease
Abstract Number: 1314

Autoantibodies and Clinical Outcomes in Pulmonary Arterial Hypertension Associated with Connective Tissue Diseases
Abstract Number: 1307

Autoantibodies in Idiopathic Interstitial Lung Disease and Interstitial Pneumonia with Autoimmune Features – a Prospective Study
Abstract Number: 1574

Autoantibodies Present in Saliva from Sjogren’s Syndrome and Non-Sjogren’s Sicca Patients Are Not Detectible in Serum
Abstract Number: 1699

Autoantibodies to M-Phase Phosphoprotein I (MPP-1: KIF20B) in Systemic Lupus Erythematosus
Abstract Number: 1341

Autoantibodies to Mi-2 Alpha and Mi-2 Beta in Patients with Myositis
Abstract Number: 392

Autoantibody Profile and Clinical Characteristics in Patients with Idiopathic Inflammatory Myopathies
Abstract Number: 1423

Autoantibody Testing in Pediatric Localized Scleroderma (LS)
Abstract Number: 137

Autoantibody-Inducing CD4 T (aiCD4 T) Cells Which Induce Systemic Lupus Erythematosus (SLE) Contain Follicular Helper T Cell in Addition to the Major IL-21-Producing CXCR5-ICOShiPD1hi Population: Self-Organized Criticality Theory As the Cause of SLE
Abstract Number: 1017

Autoantigen Pentraxin-3 Is an Inflammatory Cytokine Storms Suppressor By Switching Monocytes Pyroptosis to Apoptosis in a Complement-Dependent Manner in Rheumatoid Arthritis
Abstract Number: 2159

Autoimmune Diseases in Catalonia: A Population Based Study Using a Public Big Data Program
Abstract Number: 2275

Autoimmune Encephalitis with Concomitant Systemic Rheumatologic Auto-Antibodies

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].